GeneDx Holdings Corp. (Nasdaq: WGS), a genetic testing company focused on exome and genome sequencing for rare diseases, is back on a contrarian's buy list. On October 13, 2026, the investor known as Z (@ZeeContrarian1) raised GeneDx from 2% to 8% of his portfolio, calling it "Oversold after falling from $100 to $65." The next test is third-quarter results, for which GeneDx guided to $122 million to $124 million in revenue.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: GeneDx Holdings Corp., WGS, Nasdaq.
- Situation type: Contrarian add to a volatile diagnostics stock with heavy short interest.
- The call: Z raised WGS to 8% of his portfolio on October 13, 2026. We log it as a reiteration of his May 21, 2026 long.
- Price: WGS closed at $63.82 on October 12, 2026, versus $104.95 on September 17 and $34.51 on May 5.
- Guidance: On August 3, 2026, GeneDx reaffirmed 2026 revenue guidance of $475 million to $490 million, with exome and genome volume growth of at least 30%.
- Short interest: 5.63 million shares, or 25.2% of the float, as of September 30, 2026, per MarketBeat citing FINRA data.
- Main risk: Revenue per test is falling, and billing-practice allegations keep resurfacing.
Is WGS a good bet right now?
Bulls see a company whose test volume grows more than 30% a year and that has reached adjusted profitability. Bears see falling prices per test, billing allegations and a crowded trade.
The swings have been extreme. WGS fell 49% in one day, from $67.93 on May 4 to $34.51 on May 5, after a first-quarter guidance cut. It then roughly tripled to $104.95 by September 17 before sliding back to the mid-$60s.
Why are investors bullish on GeneDx?
- Volume. Exome and genome tests rose 32% from a year earlier to 30,785 in the second quarter of 2026, per the company's Q2 release.
- Margins. Adjusted gross margin was 70%, and adjusted net income was $0.4 million. The GAAP net loss was $17.7 million.
- Coverage wins. Carelon added outpatient genome coverage for up to 56 million covered lives from June 14, 2026, and Medi-Cal set genome pricing at 100% of the Medicare rate from July 1, 2026.
- Fresh capital. A Blackstone affiliate agreed on August 3, 2026 to buy about $5.0 million of stock at $61.00 per share, alongside a loan facility expanded to $150 million. Pro forma cash was about $188 million.
Who's making this call and why?
Z describes himself as a former Wall Street professional focused on special situations, with about 47,500 followers on X. He first went long on May 21, 2026, after the crash, writing, "My base-case scenario is a $75 price target over the next 12 months based on valuation alone." WGS first closed above $75 on August 7, 2026.
On September 30 he cautioned that "The stock may have run ahead of itself." On October 13 he raised the position again while trimming Snap from 50% to 40% of his portfolio.
Track record. In our tracking, Z is 12-11 (a .522 win rate) on 23 calls scored at 180 days against the S&P 500, with an average edge of +3.6 percentage points and a median of +6.3. Seven newer calls are 6-1 on a provisional basis. His May 21 WGS long is not yet 180 days old; at 90 days it was ahead of the S&P 500 by 74.4 points. See the scoreboard.
Another supportive voice:
- PSYwolve (@Wolfspiritbln), a small trader account, argued the late-September drop was a reimbursement story, writing, "Sector event, not a fraud event."
Who disagrees?
- StayOnCount (@StayOnCount), replying to the October 13 update, asked, "But aren't you doing the opposite of what is ideal selling a winner and adding to a loser?"
- Deep Sail Capital (@DeepSailCapital), a long/short fund we track, said on October 12 that it had put on "an industry short of genetic data companies", naming Tempus AI, CareDx, Ginkgo Bioworks and Absci. GeneDx was not on that list.
- Billing allegations. Tickeron reported that a short-seller report alleging "code stacking" billing hit the stock on September 22, 2026. Grizzly Research made similar allegations in February 2025. These are allegations, not findings.
- Pricing pressure. In the second quarter, exome and genome revenue rose 17% while volume rose 32%, which implies revenue per test fell roughly 11% from a year earlier.
What are the key facts to verify?
- Third-quarter exome and genome volume against guidance of 33,200 tests, and exome and genome revenue against $110 million to $112 million.
- Revenue per test. In the second quarter it was about $3,258 ($100.3 million over 30,785 tests).
- FINRA short interest updates and any company response to the billing allegations.
- The status of securities class actions filed after the May guidance cut, which Tickeron reported.
What would prove it right or wrong?
Signals Z is right:
- Third-quarter revenue at or above $122 million with volume of at least 33,200 tests.
- Revenue per test stabilizes as Medi-Cal and Carelon coverage ramps.
- Short interest falls while the stock rises.
Signals he is wrong:
- Another cut to the $475 million to $490 million revenue range.
- Revenue per test keeps falling faster than volume grows.
- A payer clawback or government action tied to billing practices.
This is journalism and commentary, not investment advice. We hold no position unless stated.